AU2021210993A1 - Methods and compositions for treating and preventing viral infection - Google Patents
Methods and compositions for treating and preventing viral infection Download PDFInfo
- Publication number
- AU2021210993A1 AU2021210993A1 AU2021210993A AU2021210993A AU2021210993A1 AU 2021210993 A1 AU2021210993 A1 AU 2021210993A1 AU 2021210993 A AU2021210993 A AU 2021210993A AU 2021210993 A AU2021210993 A AU 2021210993A AU 2021210993 A1 AU2021210993 A1 AU 2021210993A1
- Authority
- AU
- Australia
- Prior art keywords
- recombinant polypeptide
- viral
- sars
- receptor
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 230000009385 viral infection Effects 0.000 title claims abstract description 61
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 57
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 414
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 395
- 229920001184 polypeptide Polymers 0.000 claims abstract description 386
- 108070000030 Viral receptors Proteins 0.000 claims abstract description 150
- 239000012634 fragment Substances 0.000 claims abstract description 108
- 230000014509 gene expression Effects 0.000 claims abstract description 75
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 39
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims abstract description 31
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims abstract description 31
- 229920002971 Heparan sulfate Polymers 0.000 claims description 126
- 241000700605 Viruses Species 0.000 claims description 109
- 108091033319 polynucleotide Proteins 0.000 claims description 93
- 102000040430 polynucleotide Human genes 0.000 claims description 93
- 239000002157 polynucleotide Substances 0.000 claims description 93
- 230000027455 binding Effects 0.000 claims description 80
- 102000005962 receptors Human genes 0.000 claims description 67
- 108020003175 receptors Proteins 0.000 claims description 67
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims description 62
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 62
- 239000013598 vector Substances 0.000 claims description 62
- 108010090804 Streptavidin Proteins 0.000 claims description 61
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 55
- 230000003612 virological effect Effects 0.000 claims description 54
- 150000004676 glycans Chemical class 0.000 claims description 53
- 229920001282 polysaccharide Polymers 0.000 claims description 53
- 239000005017 polysaccharide Substances 0.000 claims description 53
- 241001678559 COVID-19 virus Species 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 49
- 208000015181 infectious disease Diseases 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 42
- 241000315672 SARS coronavirus Species 0.000 claims description 41
- 241000711573 Coronaviridae Species 0.000 claims description 40
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 40
- 239000013604 expression vector Substances 0.000 claims description 40
- 229920000669 heparin Polymers 0.000 claims description 40
- 229960002897 heparin Drugs 0.000 claims description 40
- 230000019635 sulfation Effects 0.000 claims description 37
- 238000005670 sulfation reaction Methods 0.000 claims description 37
- 244000309467 Human Coronavirus Species 0.000 claims description 36
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 35
- 108091028664 Ribonucleotide Proteins 0.000 claims description 31
- 239000002336 ribonucleotide Substances 0.000 claims description 31
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 31
- 102100027221 CD81 antigen Human genes 0.000 claims description 24
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 24
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 24
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 24
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 claims description 23
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims description 23
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 23
- 241000710781 Flaviviridae Species 0.000 claims description 21
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims description 20
- 150000001413 amino acids Chemical group 0.000 claims description 20
- -1 SRB1 Proteins 0.000 claims description 19
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 18
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims description 18
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 18
- 241000700739 Hepadnaviridae Species 0.000 claims description 17
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 17
- 208000025721 COVID-19 Diseases 0.000 claims description 16
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 15
- 101150098329 Tyro3 gene Proteins 0.000 claims description 14
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 claims description 13
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 13
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 208000001490 Dengue Diseases 0.000 claims description 10
- 206010012310 Dengue fever Diseases 0.000 claims description 10
- 230000002378 acidificating effect Effects 0.000 claims description 10
- 208000025729 dengue disease Diseases 0.000 claims description 10
- 102100032412 Basigin Human genes 0.000 claims description 9
- 241000702421 Dependoparvovirus Species 0.000 claims description 9
- 101000798441 Homo sapiens Basigin Proteins 0.000 claims description 9
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 9
- 241000701161 unidentified adenovirus Species 0.000 claims description 9
- 208000007089 vaccinia Diseases 0.000 claims description 9
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 7
- 101100150273 Caenorhabditis elegans srb-1 gene Proteins 0.000 claims description 6
- 210000002345 respiratory system Anatomy 0.000 claims description 6
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 5
- 208000020329 Zika virus infectious disease Diseases 0.000 claims description 5
- 241000287219 Serinus canaria Species 0.000 claims description 4
- 108010078070 scavenger receptors Proteins 0.000 claims description 4
- 102000014452 scavenger receptors Human genes 0.000 claims description 4
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims description 3
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 229940097496 nasal spray Drugs 0.000 claims description 3
- 125000005629 sialic acid group Chemical group 0.000 claims description 3
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 157
- 108090000623 proteins and genes Proteins 0.000 description 112
- 102000004169 proteins and genes Human genes 0.000 description 95
- 235000018102 proteins Nutrition 0.000 description 91
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 65
- 108090000054 Syndecan-2 Proteins 0.000 description 65
- 108091016585 CD44 antigen Proteins 0.000 description 63
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 42
- 241000711549 Hepacivirus C Species 0.000 description 41
- 241000282414 Homo sapiens Species 0.000 description 36
- 239000000539 dimer Substances 0.000 description 30
- 108010001857 Cell Surface Receptors Proteins 0.000 description 28
- 102000000844 Cell Surface Receptors Human genes 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 26
- 238000003556 assay Methods 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 24
- 239000002245 particle Substances 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 229960002685 biotin Drugs 0.000 description 21
- 235000020958 biotin Nutrition 0.000 description 21
- 239000011616 biotin Substances 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 21
- 241001112090 Pseudovirus Species 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 239000013603 viral vector Substances 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000001413 cellular effect Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- 108010067390 Viral Proteins Proteins 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 229920002683 Glycosaminoglycan Polymers 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 241000714177 Murine leukemia virus Species 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 102000016611 Proteoglycans Human genes 0.000 description 9
- 108010067787 Proteoglycans Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000000069 prophylactic effect Effects 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 108010022901 Heparin Lyase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 108010049224 perlecan Proteins 0.000 description 8
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 7
- 102100031673 Corneodesmosin Human genes 0.000 description 7
- 101710139375 Corneodesmosin Proteins 0.000 description 7
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 7
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 7
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 6
- 208000002109 Argyria Diseases 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 6
- 108020000999 Viral RNA Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 108010078428 env Gene Products Proteins 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000004779 membrane envelope Anatomy 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 5
- 108090000565 Capsid Proteins Proteins 0.000 description 5
- 102100023321 Ceruloplasmin Human genes 0.000 description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 description 5
- 241000709661 Enterovirus Species 0.000 description 5
- 102000010956 Glypican Human genes 0.000 description 5
- 108050001154 Glypican Proteins 0.000 description 5
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 5
- 241001135569 Human adenovirus 5 Species 0.000 description 5
- 102100034353 Integrase Human genes 0.000 description 5
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 5
- 230000010530 Virus Neutralization Effects 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 229940059329 chondroitin sulfate Drugs 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000005030 transcription termination Effects 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 230000007502 viral entry Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 3
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 3
- 241000711950 Filoviridae Species 0.000 description 3
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 102000019361 Syndecan Human genes 0.000 description 3
- 108050006774 Syndecan Proteins 0.000 description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 102000048657 human ACE2 Human genes 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 239000013607 AAV vector Substances 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102000053028 CD36 Antigens Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001529459 Enterovirus A71 Species 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108050009377 Glypican-5 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102100037220 Syndecan-4 Human genes 0.000 description 2
- 108010055215 Syndecan-4 Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 102000045598 human DPP4 Human genes 0.000 description 2
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 244000309711 non-enveloped viruses Species 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 108010084889 protein-tyrosine sulfotransferase Proteins 0.000 description 2
- 239000013608 rAAV vector Substances 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000009962 secretion pathway Effects 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical class [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101150079978 AGRN gene Proteins 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100040026 Agrin Human genes 0.000 description 1
- 108700019743 Agrin Proteins 0.000 description 1
- 241001222053 Akabane virus Species 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150045282 CD81 gene Proteins 0.000 description 1
- 101100516806 Caenorhabditis elegans nog-1 gene Proteins 0.000 description 1
- 101100369802 Caenorhabditis elegans tim-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000709734 Coxsackievirus A24 Species 0.000 description 1
- 241000709700 Coxsackievirus A9 Species 0.000 description 1
- 241000709675 Coxsackievirus B3 Species 0.000 description 1
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 229940127513 Fusion Protein Inhibitors Drugs 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 101000729659 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S8 Proteins 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 101100273730 Homo sapiens CD5 gene Proteins 0.000 description 1
- 101000928044 Homo sapiens Desmin Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101000740659 Homo sapiens Scavenger receptor class B member 1 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000837639 Homo sapiens Thyroxine-binding globulin Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 241000709716 Human enterovirus 70 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000709694 Human parechovirus 1 Species 0.000 description 1
- 241000798924 Human rhinovirus C15 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100207058 Mus musculus Tmprss2 gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000682735 Pegivirus Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000709710 Swine vesicular disease virus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 108091029474 Y RNA Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 108010044493 collagen type XVII Proteins 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 108700010904 coronavirus proteins Proteins 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000026502 entry into host cell Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 238000003167 genetic complementation Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002402 hexoses Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000051417 human SCARB1 Human genes 0.000 description 1
- 102000048799 human SERPINA7 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001180 sulfating effect Effects 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000006107 tyrosine sulfation Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/15—Peptidyl-dipeptidases (3.4.15)
- C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062965033P | 2020-01-23 | 2020-01-23 | |
| US62/965,033 | 2020-01-23 | ||
| US202063050473P | 2020-07-10 | 2020-07-10 | |
| US63/050,473 | 2020-07-10 | ||
| PCT/US2021/014818 WO2021151043A2 (en) | 2020-01-23 | 2021-01-23 | Methods and compositions for treating and preventing viral infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021210993A1 true AU2021210993A1 (en) | 2022-08-18 |
Family
ID=76991836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021210993A Abandoned AU2021210993A1 (en) | 2020-01-23 | 2021-01-23 | Methods and compositions for treating and preventing viral infection |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240002452A1 (enExample) |
| EP (1) | EP4093758A4 (enExample) |
| JP (1) | JP2023511125A (enExample) |
| KR (1) | KR20220136369A (enExample) |
| CN (1) | CN115943154A (enExample) |
| AU (1) | AU2021210993A1 (enExample) |
| BR (1) | BR112022014552A2 (enExample) |
| CA (1) | CA3165586A1 (enExample) |
| WO (1) | WO2021151043A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11518788B2 (en) | 2020-07-10 | 2022-12-06 | Avirus, Inc. | Methods and compositions for treating and preventing viral infection |
| EP4147702A1 (en) * | 2021-09-13 | 2023-03-15 | Medizinische Universität Graz | Novel combination of heparin and ace2 decoys for the treatment of covid-19 |
| WO2023081958A1 (en) * | 2021-11-11 | 2023-05-19 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Antiviral agent comprising a cellular entry receptor and fc region component |
| CN114989269B (zh) * | 2022-06-30 | 2023-09-19 | 天康制药股份有限公司 | 一种牛赤羽免疫原性抗原及疫苗 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6297048B1 (en) * | 1992-02-04 | 2001-10-02 | Chiron Corporation | Hepatitis therapeutics |
| WO1999037317A1 (en) * | 1998-01-24 | 1999-07-29 | Bristol-Myers Squibb Company | Artificial proteoglycans |
| WO2001013910A2 (en) * | 1999-08-25 | 2001-03-01 | Massachusetts Institute Of Technology | Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry |
| US6511832B1 (en) * | 1999-10-06 | 2003-01-28 | Texas A&M University System | In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase |
| AU2001288392A1 (en) * | 2000-08-30 | 2002-03-13 | University Of Delaware | Delivery system for heparin-binding growth factors |
| CN1884303A (zh) * | 2005-06-20 | 2006-12-27 | 中国医学科学院基础医学研究所 | SARS－CoV病毒结构蛋白的融合蛋白及其高量表达与纯化和用途 |
| AT505262A1 (de) * | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
| JP7332157B2 (ja) * | 2017-01-24 | 2023-08-23 | ノースウェスタン ユニバーシティ | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 |
| US11518788B2 (en) * | 2020-07-10 | 2022-12-06 | Avirus, Inc. | Methods and compositions for treating and preventing viral infection |
-
2021
- 2021-01-23 BR BR112022014552A patent/BR112022014552A2/pt not_active IP Right Cessation
- 2021-01-23 JP JP2022544076A patent/JP2023511125A/ja active Pending
- 2021-01-23 WO PCT/US2021/014818 patent/WO2021151043A2/en not_active Ceased
- 2021-01-23 AU AU2021210993A patent/AU2021210993A1/en not_active Abandoned
- 2021-01-23 KR KR1020227027998A patent/KR20220136369A/ko active Pending
- 2021-01-23 EP EP21744864.6A patent/EP4093758A4/en not_active Withdrawn
- 2021-01-23 CA CA3165586A patent/CA3165586A1/en active Pending
- 2021-01-23 CN CN202180010808.6A patent/CN115943154A/zh active Pending
-
2022
- 2022-10-17 US US18/047,150 patent/US20240002452A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021151043A2 (en) | 2021-07-29 |
| CA3165586A1 (en) | 2021-07-29 |
| CN115943154A (zh) | 2023-04-07 |
| BR112022014552A2 (pt) | 2022-10-25 |
| US20240002452A1 (en) | 2024-01-04 |
| KR20220136369A (ko) | 2022-10-07 |
| JP2023511125A (ja) | 2023-03-16 |
| EP4093758A4 (en) | 2024-02-14 |
| WO2021151043A3 (en) | 2021-09-10 |
| EP4093758A2 (en) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11518788B2 (en) | Methods and compositions for treating and preventing viral infection | |
| US20240002452A1 (en) | Methods and compositions for treating and preventing viral infection | |
| US20230193235A1 (en) | Modified angiotensin-converting enzyme 2 (ace2) and use thereof | |
| CN112321688A (zh) | 稳定的冠状病毒重组蛋白二聚体及其表达载体 | |
| US20240327815A1 (en) | Multivalent polypeptide constructs capable of binding viral spike proteins and methods of using the same | |
| US20230331815A1 (en) | Methods and compositions for treating viral infection | |
| Zhang et al. | Identification of the receptor binding domain of the mouse mammary tumor virus envelope protein | |
| US20110305670A1 (en) | Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection | |
| WO2023081958A1 (en) | Antiviral agent comprising a cellular entry receptor and fc region component | |
| US20060258577A1 (en) | Antiviral agents for the treatment, control and prevention of infections by coronaviruses | |
| US20240398911A1 (en) | Engineered receptors and monoclonal antibodies for cronaviruses and uses thereof | |
| US7488481B2 (en) | Polypeptides derived from anti-HIV-1 gp120 antibodies that abrogate gp120 binding to CCR5 | |
| EP4214242A1 (en) | Vectorized antibodies for anti-viral therapy | |
| US10888615B2 (en) | Neutralizing human monoclonal antibody 8D6 against HCV infection | |
| WO2022104081A2 (en) | Modified secreted hepatitis c virus (hcv) e1e2 glycoproteins and methods of use thereof | |
| US7341728B2 (en) | Internalisation of virus into cells | |
| US20240307486A1 (en) | Methods and compositions for high-potency polypeptide-based protein inhibition | |
| Tada et al. | Prophylaxis and Treatment of SARS-CoV-2 infection by an ACE2 Receptor Decoy | |
| WO2024205404A1 (en) | Novel capsid engineered aav vectors for liver-directed gene therapy | |
| CN116601291A (zh) | 修饰的血管紧张素转换酶2（ace2）及其用途 | |
| Naik | In vitro infectivity of the Hepatitis C Virus in the context of humoral immunity and immune escape | |
| Hudson | Analysis of diversity of hepatitis C virus glycoproteins E1 and E2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |